Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
However, the IM route was the top-ranked statistically but without clinical significance
SlGSTU38 acted as a susceptibility factor and outlined the dual role of the proviral SlGSTU38 protein
The inhibitory ability of the designed peptide (CAND) was then verified using FPA competition analysis to ensure its continued effectiveness in inhibiting the interaction between FOXO4 and p53 TAD (Figure
Not evaluated by FDA
is co-founder and shareholder of ROSCUE Therapeutics GmbH
Standard IGF-1 IGF-1 LR3's reduced IGFBP binding makes it the preferred choice for in vitro research where consistent, predictable growth factor exposure is required
US$ 27.38
US$ 22.90
US$ 21.00
US$ 27.09
US$ 25.38
US$ 27.55
